US6726918B1
(en)
|
2000-07-05 |
2004-04-27 |
Oculex Pharmaceuticals, Inc. |
Methods for treating inflammation-mediated conditions of the eye
|
DE60114229T2
(de)
|
2000-11-29 |
2006-07-06 |
Allergan, Inc., Irvine |
Verhinderung von transplantatabstossung im auge
|
US7431710B2
(en)
|
2002-04-08 |
2008-10-07 |
Glaukos Corporation |
Ocular implants with anchors and methods thereof
|
US20050048099A1
(en)
|
2003-01-09 |
2005-03-03 |
Allergan, Inc. |
Ocular implant made by a double extrusion process
|
US7799336B2
(en)
|
2004-04-30 |
2010-09-21 |
Allergan, Inc. |
Hypotensive lipid-containing biodegradable intraocular implants and related methods
|
US7993634B2
(en)
|
2004-04-30 |
2011-08-09 |
Allergan, Inc. |
Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
|
US20050244469A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Extended therapeutic effect ocular implant treatments
|
US8685435B2
(en)
|
2004-04-30 |
2014-04-01 |
Allergan, Inc. |
Extended release biodegradable ocular implants
|
US9498457B2
(en)
|
2004-04-30 |
2016-11-22 |
Allergan, Inc. |
Hypotensive prostamide-containing biodegradable intraocular implants and related implants
|
US8722097B2
(en)
|
2004-04-30 |
2014-05-13 |
Allergan, Inc. |
Oil-in-water method for making polymeric implants containing a hypotensive lipid
|
US8529927B2
(en)
*
|
2004-04-30 |
2013-09-10 |
Allergan, Inc. |
Alpha-2 agonist polymeric drug delivery systems
|
US8673341B2
(en)
|
2004-04-30 |
2014-03-18 |
Allergan, Inc. |
Intraocular pressure reduction with intracameral bimatoprost implants
|
WO2006078320A2
(en)
|
2004-08-04 |
2006-07-27 |
Brookwood Pharmaceuticals, Inc. |
Methods for manufacturing delivery devices and devices thereof
|
AU2014201844B2
(en)
*
|
2004-08-13 |
2016-06-16 |
Allergan, Inc |
Ocular implant made by a double extrusion process
|
AU2012216644B2
(en)
*
|
2004-08-13 |
2014-04-10 |
Allergan, Inc. |
Ocular implant made by a double extrusion process
|
AU2016228285B2
(en)
*
|
2004-08-13 |
2018-06-28 |
Allergan, Inc. |
Ocular implant made by a double extrusion process
|
US7931909B2
(en)
|
2005-05-10 |
2011-04-26 |
Allergan, Inc. |
Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
|
WO2007037849A2
(en)
|
2005-09-16 |
2007-04-05 |
Allergan, Inc. |
Compositions and methods for the intraocular transport of therapeutic agents
|
WO2007038453A2
(en)
*
|
2005-09-26 |
2007-04-05 |
Advanced Ocular Systems Limited |
Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
|
PL1959925T3
(pl)
*
|
2005-12-02 |
2017-05-31 |
(Osi) Eyetech, Inc. |
Mikrocząstki o kontrolowanym uwalnianiu
|
US20070202186A1
(en)
|
2006-02-22 |
2007-08-30 |
Iscience Interventional Corporation |
Apparatus and formulations for suprachoroidal drug delivery
|
AU2007235232B2
(en)
|
2006-04-06 |
2013-07-11 |
Nupathe Inc. |
Implants for the treatment of dopamine associated states
|
US20070260203A1
(en)
*
|
2006-05-04 |
2007-11-08 |
Allergan, Inc. |
Vasoactive agent intraocular implant
|
JP2010500364A
(ja)
*
|
2006-08-07 |
2010-01-07 |
ボーシュ アンド ローム インコーポレイティド |
後部眼科疾患を治療、または軽減、または改善、または緩和するための組成物と方法
|
JP5694664B2
(ja)
*
|
2006-09-29 |
2015-04-01 |
サーモディクス,インコーポレイティド |
生分解性眼用インプラント及び眼の病気を治療する方法
|
US20080103368A1
(en)
*
|
2006-10-17 |
2008-05-01 |
Ari Craine |
Methods, devices, and computer program products for detecting syndromes
|
US8039010B2
(en)
*
|
2006-11-03 |
2011-10-18 |
Allergan, Inc. |
Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
|
US8969415B2
(en)
*
|
2006-12-01 |
2015-03-03 |
Allergan, Inc. |
Intraocular drug delivery systems
|
CN101678034A
(zh)
*
|
2007-03-30 |
2010-03-24 |
佛维雅制药股份有限公司 |
治疗新血管眼病的方法
|
US8642067B2
(en)
|
2007-04-02 |
2014-02-04 |
Allergen, Inc. |
Methods and compositions for intraocular administration to treat ocular conditions
|
US20080317805A1
(en)
*
|
2007-06-19 |
2008-12-25 |
Mckay William F |
Locally administrated low doses of corticosteroids
|
US9125807B2
(en)
*
|
2007-07-09 |
2015-09-08 |
Incept Llc |
Adhesive hydrogels for ophthalmic drug delivery
|
US20170360609A9
(en)
|
2007-09-24 |
2017-12-21 |
Ivantis, Inc. |
Methods and devices for increasing aqueous humor outflow
|
WO2009085952A1
(en)
|
2007-12-20 |
2009-07-09 |
Brookwood Pharmaceuticals, Inc. |
Process for preparing microparticles having a low residual solvent volume
|
EP2259833A1
(en)
|
2008-03-05 |
2010-12-15 |
Ivantis, INC. |
Methods and apparatus for treating glaucoma
|
US8524267B2
(en)
*
|
2008-04-18 |
2013-09-03 |
Warsaw Orthopedic, Inc. |
Dexamethasone formulations in a biodegradable material
|
US8557273B2
(en)
*
|
2008-04-18 |
2013-10-15 |
Medtronic, Inc. |
Medical devices and methods including polymers having biologically active agents therein
|
US8889173B2
(en)
|
2008-04-18 |
2014-11-18 |
Warsaw Orthopedic, Inc. |
Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
|
US8946277B2
(en)
|
2008-04-18 |
2015-02-03 |
Warsaw Orthopedic, Inc. |
Clonidine formulations in a biodegradable polymer carrier
|
USRE48948E1
(en)
|
2008-04-18 |
2022-03-01 |
Warsaw Orthopedic, Inc. |
Clonidine compounds in a biodegradable polymer
|
US9610243B2
(en)
|
2008-04-18 |
2017-04-04 |
Warsaw Orthopedic, Inc. |
Clonidine compounds in a biodegradable polymer
|
US9095404B2
(en)
|
2008-05-12 |
2015-08-04 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
US10588855B2
(en)
|
2008-05-12 |
2020-03-17 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
US10064819B2
(en)
|
2008-05-12 |
2018-09-04 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
US9877973B2
(en)
|
2008-05-12 |
2018-01-30 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
WO2009140246A2
(en)
|
2008-05-12 |
2009-11-19 |
University Of Utah Research Foundation |
Intraocular drug delivery device and associated methods
|
KR20110094029A
(ko)
|
2008-11-10 |
2011-08-19 |
알렉시온 파마슈티칼스, 인코포레이티드 |
보체-관련된 장애를 치료하는 방법 및 조성물
|
US8551167B2
(en)
|
2008-11-20 |
2013-10-08 |
Insight Innovations, Llc |
Intraocular implant cell migration inhibition system
|
WO2010059214A2
(en)
|
2008-11-20 |
2010-05-27 |
Insight Innovations, Llc |
Biocompatible biodegradable intraocular implant system
|
US9943402B2
(en)
|
2008-11-20 |
2018-04-17 |
Insight Innovations, Llc |
Micropatterned intraocular implant
|
US20120232649A1
(en)
|
2008-11-20 |
2012-09-13 |
Insight Innovations, Llc |
Intraocular Lens Cell Migration Inhibition System
|
CA3045436A1
(en)
|
2009-01-29 |
2010-08-05 |
Forsight Vision4, Inc. |
Posterior segment drug delivery
|
US8623395B2
(en)
|
2010-01-29 |
2014-01-07 |
Forsight Vision4, Inc. |
Implantable therapeutic device
|
JP5890182B2
(ja)
|
2009-02-12 |
2016-03-22 |
インセプト エルエルシー |
ヒドロゲルプラグによる薬物送達
|
US9636255B2
(en)
|
2009-02-13 |
2017-05-02 |
Dose Medical Corporation |
Uveoscleral drug delivery implant and methods for implanting the same
|
EP2752427A1
(en)
|
2009-02-24 |
2014-07-09 |
Alexion Pharmaceuticals, Inc. |
Antibodies containing therapeutic TPO/EPO mimetic peptides
|
US20100239632A1
(en)
*
|
2009-03-23 |
2010-09-23 |
Warsaw Orthopedic, Inc. |
Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
|
US20100278897A1
(en)
*
|
2009-05-01 |
2010-11-04 |
Allergan, Inc. |
Intraocular bioactive agent delivery system with molecular partitioning system
|
US10206813B2
(en)
|
2009-05-18 |
2019-02-19 |
Dose Medical Corporation |
Implants with controlled drug delivery features and methods of using same
|
US20100314162A1
(en)
*
|
2009-06-10 |
2010-12-16 |
Ppg Industries Ohio, Inc. |
Microporous material derived from renewable polymers and articles prepared therefrom
|
EP2445937B1
(en)
|
2009-06-23 |
2017-05-24 |
Alexion Pharmaceuticals, Inc. |
Bispecific antibodies that bind to complement proteins
|
WO2011006078A1
(en)
|
2009-07-09 |
2011-01-13 |
Ivantis, Inc. |
Single operator device for delivering an ocular implant
|
CA2766192C
(en)
|
2009-07-09 |
2017-10-24 |
Ivantis, Inc. |
Ocular implants for residing partially in schlemm's canal
|
EP2477612A2
(en)
*
|
2009-09-17 |
2012-07-25 |
Evonik Degussa Corporation |
Implant devices that differ by release profile and methods of making and using same
|
JP2013509448A
(ja)
*
|
2009-11-02 |
2013-03-14 |
ニューパス インコーポレーテッド |
パーキンソン病の治療方法
|
CN102724951A
(zh)
|
2009-11-09 |
2012-10-10 |
阿勒根公司 |
用于刺激毛发生长的组合物和方法
|
US8529492B2
(en)
|
2009-12-23 |
2013-09-10 |
Trascend Medical, Inc. |
Drug delivery devices and methods
|
US10166142B2
(en)
|
2010-01-29 |
2019-01-01 |
Forsight Vision4, Inc. |
Small molecule delivery with implantable therapeutic device
|
ES2623799T3
(es)
|
2010-04-30 |
2017-07-12 |
Alexion Pharmaceuticals, Inc. |
Anticuerpos anti-C5a y métodos para el uso de los anticuerpos
|
CA2803588A1
(en)
|
2010-06-22 |
2011-12-29 |
The Regents Of The University Of Colorado, A Body Corporate |
Antibodies to the c3d fragment of complement component 3
|
EP2595602B1
(en)
|
2010-07-21 |
2018-05-23 |
Allergan, Inc. |
SUSTAINED RELEASE siRNA FOR OCULAR DRUG DELIVERY
|
HRP20211909T1
(hr)
|
2010-08-05 |
2022-03-18 |
Forsight Vision4, Inc. |
Uređaj za liječenja oka
|
EP2600876B1
(en)
|
2010-08-05 |
2015-04-29 |
Forsight Vision4, Inc. |
Combined drug delivery methods and apparatus
|
PL2600930T3
(pl)
|
2010-08-05 |
2021-09-06 |
Forsight Vision4, Inc. |
Urządzenie wstrzykujące do dostarczania leku
|
JP5996544B2
(ja)
|
2010-10-15 |
2016-09-21 |
クリアサイド・バイオメディカル・インコーポレーテッドClearside Biomedical Incorporated |
眼球アクセス用装置
|
WO2012068549A2
(en)
|
2010-11-19 |
2012-05-24 |
Forsight Vision4, Inc. |
Therapeutic agent formulations for implanted devices
|
US9668915B2
(en)
|
2010-11-24 |
2017-06-06 |
Dose Medical Corporation |
Drug eluting ocular implant
|
AU2012212066A1
(en)
|
2011-02-03 |
2013-08-15 |
Alexion Pharmaceuticals, Inc. |
Use of an anti-CD200 antibody for prolonging the survival of allografts
|
US10245178B1
(en)
|
2011-06-07 |
2019-04-02 |
Glaukos Corporation |
Anterior chamber drug-eluting ocular implant
|
RS60051B1
(sr)
*
|
2011-06-10 |
2020-04-30 |
Ramscor Inc |
Formulacije sa produženim oslobađanjem za isporuku proteina u oko i postupci njihove pripreme
|
US8657776B2
(en)
|
2011-06-14 |
2014-02-25 |
Ivantis, Inc. |
Ocular implants for delivery into the eye
|
US10398592B2
(en)
|
2011-06-28 |
2019-09-03 |
Forsight Vision4, Inc. |
Diagnostic methods and apparatus
|
LT2755600T
(lt)
|
2011-09-16 |
2021-04-26 |
Forsight Vision4, Inc. |
Skysčio pakeitimo aparatas
|
US10226417B2
(en)
|
2011-09-16 |
2019-03-12 |
Peter Jarrett |
Drug delivery systems and applications
|
US8663150B2
(en)
|
2011-12-19 |
2014-03-04 |
Ivantis, Inc. |
Delivering ocular implants into the eye
|
WO2013116061A1
(en)
|
2012-02-03 |
2013-08-08 |
Forsight Vision4, Inc. |
Insertion and removal methods and apparatus for therapeutic devices
|
WO2013119959A1
(en)
|
2012-02-09 |
2013-08-15 |
Novus International Inc. |
Heteroatom containing cyclic dimers
|
US9358156B2
(en)
|
2012-04-18 |
2016-06-07 |
Invantis, Inc. |
Ocular implants for delivery into an anterior chamber of the eye
|
BR112015000494A2
(pt)
|
2012-07-12 |
2017-06-27 |
Novus Int Inc |
matriz e composições da camada para a proteção dos biotivos
|
JP2015535212A
(ja)
|
2012-08-17 |
2015-12-10 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト |
補体活性化を検出するための組成物および方法
|
US10413620B2
(en)
|
2012-08-17 |
2019-09-17 |
The Regents Of The University Of Colorado, A Body Corporate |
Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
|
CA2886081A1
(en)
|
2012-09-27 |
2014-04-03 |
Allergan, Inc. |
Biodegradable drug delivery systems for the sustained release of proteins
|
WO2014066644A1
(en)
*
|
2012-10-26 |
2014-05-01 |
Allergan, Inc. |
Ketorolac-containing sustained release drug delivery systems
|
US20150272877A1
(en)
*
|
2012-10-26 |
2015-10-01 |
Allergan, Inc. |
Ketorolac-containing sustained release drug delivery systems
|
WO2014066653A1
(en)
*
|
2012-10-26 |
2014-05-01 |
Allergan, Inc. |
Ketorolac-containing sustained release intraocular drug delivery systems
|
BR112015010566A2
(pt)
|
2012-11-08 |
2017-07-11 |
Clearside Biomedical Inc |
métodos e dispositivos para o tratamento de doenças oculares em indivíduos humanos
|
WO2014085450A1
(en)
|
2012-11-28 |
2014-06-05 |
Ivantis, Inc. |
Apparatus for delivering ocular implants into an anterior chamber of the eye
|
KR20150119254A
(ko)
|
2013-02-15 |
2015-10-23 |
알러간, 인코포레이티드 |
지속된 약물 전달 임플란트
|
WO2014152959A1
(en)
|
2013-03-14 |
2014-09-25 |
Forsight Vision4, Inc. |
Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
|
US10517759B2
(en)
|
2013-03-15 |
2019-12-31 |
Glaukos Corporation |
Glaucoma stent and methods thereof for glaucoma treatment
|
AU2014241163B2
(en)
|
2013-03-28 |
2018-09-27 |
Forsight Vision4, Inc. |
Ophthalmic implant for delivering therapeutic substances
|
EP3473272A1
(en)
|
2013-03-29 |
2019-04-24 |
Alexion Pharmaceuticals, Inc. |
Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
|
BR112015027762A2
(pt)
|
2013-05-03 |
2017-08-29 |
Clearside Biomedical Inc |
Aparelho e métodos para injeção ocular
|
EP3003454B1
(en)
|
2013-06-03 |
2020-01-08 |
Clearside Biomedical, Inc. |
Apparatus for drug delivery using multiple reservoirs
|
WO2015021166A2
(en)
|
2013-08-07 |
2015-02-12 |
Alexion Pharmaceuticals, Inc. |
Atypical hemolytic uremic syndrome biomarker proteins
|
JP6543431B2
(ja)
*
|
2013-10-10 |
2019-07-10 |
ユニバーシティー オブ ユタ リサーチ ファウンデーションUniversity of Utah Research Foundation |
眼内薬物送達デバイスおよび付随する方法
|
RU2650614C2
(ru)
|
2013-10-31 |
2018-04-16 |
Аллерган, Инк. |
Внутриглазные имплантаты, содержащие простамид, и способы их применения
|
LT3065793T
(lt)
*
|
2013-11-08 |
2021-05-10 |
Hollister Incorporated |
Kateteriai su oleofiline danga
|
WO2015073895A1
(en)
*
|
2013-11-15 |
2015-05-21 |
Allergan, Inc. |
Methods of treatment of ocular conditions with a sustained drug delivery implant
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
WO2015184173A1
(en)
|
2014-05-29 |
2015-12-03 |
Dose Medical Corporation |
Implants with controlled drug delivery features and methods of using same
|
BR112016029864A2
(pt)
*
|
2014-06-17 |
2017-08-22 |
Clearside Biomedical Inc |
métodos e dispositivos para tratamento de desordens oculares posteriores.
|
WO2015196085A2
(en)
|
2014-06-20 |
2015-12-23 |
Clearside Biomedical, Inc. |
Variable diameter cannula and methods for controlling insertion depth for medicament delivery
|
US10709547B2
(en)
|
2014-07-14 |
2020-07-14 |
Ivantis, Inc. |
Ocular implant delivery system and method
|
MY182497A
(en)
|
2014-07-15 |
2021-01-25 |
Forsight Vision4 Inc |
Ocular implant delivery device and method
|
CA2957548A1
(en)
|
2014-08-08 |
2016-02-11 |
Forsight Vision4, Inc. |
Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
|
CN115957347A
(zh)
|
2014-10-03 |
2023-04-14 |
纳米提克斯有限责任公司 |
用于抑制可溶生物分子的生物活性的组合物以及方法
|
WO2016077371A1
(en)
|
2014-11-10 |
2016-05-19 |
Forsight Vision4, Inc. |
Expandable drug delivery devices and method of use
|
FR3028410A1
(fr)
|
2014-11-18 |
2016-05-20 |
Pierre Coulon |
Implant capsulaire multifonctionnel
|
AU2015362621B2
(en)
|
2014-12-15 |
2019-01-17 |
The Johns Hopkins University |
Sunitinib formulations and methods for use thereof in treatment of ocular disorders
|
US20180215801A1
(en)
|
2015-01-29 |
2018-08-02 |
Board Of Trustees Of Michigan State University |
Cryptic polypeptides and uses thereof
|
WO2016144832A1
(en)
|
2015-03-06 |
2016-09-15 |
Envisia Therapeutics, Inc. |
Implant applicators and methods of administering implants
|
CA2979397A1
(en)
|
2015-03-12 |
2016-09-15 |
Board Of Trustees Of Michigan State University |
Compositions and methods for measuring c-peptide binding and diagnosing immune-mediated diseases
|
WO2016183183A1
(en)
|
2015-05-11 |
2016-11-17 |
The Johns Hopkins University |
Autoimmune antibodies for use in inhibiting cancer cell growth
|
EP3294212B1
(en)
|
2015-05-12 |
2023-10-25 |
Incept, LLC |
Drug delivery from hydrogels
|
EP3324902A1
(en)
|
2015-07-22 |
2018-05-30 |
Incept, LLC |
Coated punctal plug
|
EP3324944A4
(en)
|
2015-07-23 |
2019-04-03 |
Aerie Pharmaceuticals, Inc. |
INTRAVITREAL AGGREGATION SYSTEMS FOR THE TREATMENT OF EYE DISEASE
|
AU2016307951B2
(en)
|
2015-08-14 |
2021-04-01 |
Alcon Inc. |
Ocular implant with pressure sensor and delivery system
|
US11925578B2
(en)
|
2015-09-02 |
2024-03-12 |
Glaukos Corporation |
Drug delivery implants with bi-directional delivery capacity
|
US11564833B2
(en)
|
2015-09-25 |
2023-01-31 |
Glaukos Corporation |
Punctal implants with controlled drug delivery features and methods of using same
|
GB201519811D0
(en)
*
|
2015-11-10 |
2015-12-23 |
Univ Belfast |
Ocular compositions
|
CN114469872A
(zh)
|
2015-11-12 |
2022-05-13 |
灰色视觉公司 |
用于治疗的聚集性微粒
|
BR112018010063A2
(pt)
|
2015-11-20 |
2018-11-13 |
Forsight Vision4 Inc |
estruturas porosas para dispositivos de administração de medicamento de liberação estendida
|
WO2017106517A1
(en)
|
2015-12-15 |
2017-06-22 |
Ivantis, Inc. |
Ocular implant and delivery system
|
US10390901B2
(en)
|
2016-02-10 |
2019-08-27 |
Clearside Biomedical, Inc. |
Ocular injection kit, packaging, and methods of use
|
PT109154B
(pt)
*
|
2016-02-12 |
2019-11-05 |
Univ De Coimbra |
Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos
|
WO2017176886A1
(en)
|
2016-04-05 |
2017-10-12 |
Forsight Vision4, Inc. |
Implantable ocular drug delivery devices
|
WO2017176762A1
(en)
|
2016-04-06 |
2017-10-12 |
Nanotics, Llc |
Particles comprising subparticles or nucleic acid scaffolds
|
EP3442479A1
(en)
|
2016-04-20 |
2019-02-20 |
Harold Alexander Heitzmann |
Bioresorbable ocular drug delivery device
|
CA3062845A1
(en)
|
2016-05-02 |
2017-11-09 |
Clearside Biomedical, Inc. |
Systems and methods for ocular drug delivery
|
US10973681B2
(en)
|
2016-08-12 |
2021-04-13 |
Clearside Biomedical, Inc. |
Devices and methods for adjusting the insertion depth of a needle for medicament delivery
|
BR112019019452A2
(pt)
|
2017-03-23 |
2020-04-14 |
Graybug Vision Inc |
composto, e, uso de um composto
|
US11160870B2
(en)
|
2017-05-10 |
2021-11-02 |
Graybug Vision, Inc. |
Extended release microparticles and suspensions thereof for medical therapy
|
WO2018231485A1
(en)
|
2017-06-13 |
2018-12-20 |
Innfocus, Inc. |
Systems, methods, and apparatus for treatment of glaucoma
|
US20190062428A1
(en)
|
2017-06-19 |
2019-02-28 |
Surface Oncology, Inc. |
Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
|
AU2018301393A1
(en)
|
2017-07-11 |
2020-02-06 |
Compass Therapeutics Llc |
Agonist antibodies that bind human CD137 and uses thereof
|
EP3658184B1
(en)
|
2017-07-27 |
2023-09-06 |
Alexion Pharmaceuticals, Inc. |
High concentration anti-c5 antibody formulations
|
US10584306B2
(en)
|
2017-08-11 |
2020-03-10 |
Board Of Regents Of The University Of Oklahoma |
Surfactant microemulsions
|
EP3684811A2
(en)
|
2017-08-17 |
2020-07-29 |
Massachusetts Institute of Technology |
Multiple specificity binders of cxc chemokines and uses thereof
|
SG11202001379WA
(en)
|
2017-09-08 |
2020-03-30 |
Bristol Myers Squibb Co |
Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash)
|
US11761963B2
(en)
|
2017-09-27 |
2023-09-19 |
Alexion Pharmaceuticals, Inc. |
Biomarker signature for predicting tumor response to anti-CD200 therapy
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
CA3082891A1
(en)
|
2017-11-21 |
2019-05-31 |
Forsight Vision4, Inc. |
Fluid exchange apparatus for expandable port delivery system and methods of use
|
EP3765524A4
(en)
|
2018-03-14 |
2021-12-22 |
Surface Oncology, Inc. |
Antibodies for binding CD39 and uses thereof
|
US11332524B2
(en)
|
2018-03-22 |
2022-05-17 |
Surface Oncology, Inc. |
Anti-IL-27 antibodies and uses thereof
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
CN112105733A
(zh)
|
2018-04-19 |
2020-12-18 |
查美特制药公司 |
合成rig-i样受体激动剂
|
JP2021525243A
(ja)
|
2018-05-21 |
2021-09-24 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
Nk細胞による標的細胞の殺傷を増進するための組成物および方法
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
WO2020018715A1
(en)
|
2018-07-17 |
2020-01-23 |
Massachusetts Institute Of Technology |
Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
|
US20210309746A1
(en)
|
2018-08-09 |
2021-10-07 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
WO2020033923A1
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antigen binding agents that bind cd277 and uses thereof
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
SG11202104864QA
(en)
|
2018-11-13 |
2021-06-29 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
AU2020208397A1
(en)
|
2019-01-16 |
2021-08-12 |
Compass Therapeutics Llc |
Formulations of antibodies that bind human CD137 and uses thereof
|
EP3920899A2
(en)
|
2019-02-08 |
2021-12-15 |
The UAB Research Foundation |
Immunotherapy for the treatment and prevention of inflammatory bowel disease
|
AU2020283135A1
(en)
*
|
2019-05-31 |
2022-01-06 |
Dose Medical Corporation |
Bioerodible polyester polymer implants and related methods of use
|
BR112021026265A2
(pt)
|
2019-06-27 |
2022-06-14 |
Layerbio Inc |
Métodos e sistemas de entrega de dispositivos oculares
|
BR112022002351A2
(pt)
|
2019-09-16 |
2022-07-19 |
Surface Oncology Inc |
Composições e métodos de anticorpo anti-cd39
|
EP4034559A1
(en)
|
2019-09-25 |
2022-08-03 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
WO2021067526A1
(en)
|
2019-10-02 |
2021-04-08 |
Alexion Pharmaceuticals, Inc. |
Complement inhibitors for treating drug-induced complement-mediated response
|
MX2022004825A
(es)
|
2019-10-23 |
2022-10-10 |
Regeneron Pharma |
Agonistas sintéticos del receptor similar a rig i.
|
WO2021080682A1
(en)
|
2019-10-24 |
2021-04-29 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human cd161 and uses thereof
|
IL295357A
(en)
|
2020-02-06 |
2022-10-01 |
Ocular Therapeutix Inc |
Preparations and methods for the treatment of eye diseases
|
CN115461040A
(zh)
|
2020-03-25 |
2022-12-09 |
视觉治疗股份有限公司 |
含有酪氨酸激酶抑制剂的眼用植入物
|
EP4150338A1
(en)
|
2020-05-15 |
2023-03-22 |
Alexion Pharmaceuticals, Inc. |
Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease
|
AU2022205382A1
(en)
|
2021-01-11 |
2023-06-22 |
Alcon Inc. |
Systems and methods for viscoelastic delivery
|
EP4334348A1
(en)
|
2021-05-07 |
2024-03-13 |
Surface Oncology, LLC |
Anti-il-27 antibodies and uses thereof
|
WO2022251446A1
(en)
|
2021-05-28 |
2022-12-01 |
Alexion Pharmaceuticals, Inc. |
Methods for detecting cm-tma biomarkers
|
WO2023230128A1
(en)
|
2022-05-25 |
2023-11-30 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
US20240025987A1
(en)
|
2022-05-25 |
2024-01-25 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
WO2024037982A1
(en)
|
2022-08-16 |
2024-02-22 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical formulations of nintedanib for intraocular use
|
WO2024054436A1
(en)
|
2022-09-06 |
2024-03-14 |
Alexion Pharmaceuticals, Inc. |
Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
|